Lisdexamfetamine in the treatment of methamphetamine dependence: A randomised, placebo‐controlled trial

Lisdexamfetamine appears to reduce methamphetamine use over a 12-week treatment period, although there is only weak evidence that reduced use is maintained during the last 4 weeks.

Authors

Institutions

Publication Details

Journal
Addiction
Published
2024-12-19
DOI
https://doi.org/10.1111/add.16730
Citations
8
Primary Topic
Schizophrenia research and treatment
Type
article
Field-Weighted Citation Impact
3.08

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Lisdexamfetamine in the treatment of methamphetamine dependence: A randomised, placebo‐controlled trial

Adrian Dunlop, Raimondo Bruno, James Ward, Brendan Clifford et al.
8 citations
Addiction
Schizophrenia research and treatment
3.08
article

Lisdexamfetamine in the treatment of methamphetamine dependence: A randomised, placebo‐controlled trial

Adrian Dunlop, Raimondo Bruno, James Ward, Brendan Clifford, Nadine Ezard, Robert Ali, Shalini Arunogiri, Amanda Baker, Krista J. Siefried, Dan I. Lubman, Rebecca McKetin, Mark W. Donoghoe, Nick Olsen, Paul Haber, Andrew Carr, Nicholas Lintzeris, Michael Farrell, Michelle Hall, Robert Graham
article en
8 citations

Abstract

Lisdexamfetamine appears to reduce methamphetamine use over a 12-week treatment period, although there is only weak evidence that reduced use is maintained during the last 4 weeks.

AddictionVol. 120(7)
The University of Sydney (AU), University of Tasmania (AU), New South Wales Department of Health (AU), The University of Queensland (AU), UNSW Sydney (AU), St Vincent's Hospital Melbourne (AU), St Vincent's Hospital Sydney (AU), Eastern Health (AU), National Centre for Clinical Research on Emerging Drugs (AU), Sydney Local Health District (AU), South Eastern Sydney Local Health District (AU), Hunter New England Local Health District (AU), Monash University (AU), The University of Adelaide (AU), University of Newcastle Australia (AU)
University of New South Wales, Department of Health, State Government of Victoria, State Government of Victoria, Medical Research Council, National Health and Medical Research Council
Good health and well-being
Openalex Percentile: Top 7%
Schizophrenia research and treatment
3.08
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.